- Conditions
- Hematologic Neoplasms, Multiple Myeloma, Anemia, Aplastic, Hemoglobinuria, Paroxysmal, Myelofibrosis
- Interventions
- busulfan, and melphalan, and alemtuzumab
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 279
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, Rituximab, Alemtuzumab, Allogeneic Stem Cell Infusion
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- Interventions
- Alemtuzumab
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 7
- States / cities
- La Jolla, California • La Verne, California • Aurora, Colorado + 4 more
- Conditions
- Preleukemia, Myeloproliferative Disorders, Lymphoma, Myeloma, Graft Versus Host Disease
- Interventions
- Fludarabine, Melphalan, Campath
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute T-Cell Leukemia-Lymphoma
- Interventions
- Alemtuzumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
- Interventions
- Bendamustine Hydrochloride, Alemtuzumab
- Drug · Biological
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Sickle Cell Disease
- Interventions
- Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus
- Procedure · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
- Interventions
- Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2031
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Orange, California • San Diego, California + 20 more
- Conditions
- Multiple Sclerosis
- Interventions
- Alemtuzumab (GZ402673)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
- Interventions
- CD34 Stem Cell Selection Therapy
- Biological
- Lead sponsor
- Diane George
- Other
- Eligibility
- Up to 40 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell
- Interventions
- Alemtuzumab (Campath), EPOCH
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 17 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- alemtuzumab, asparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, vincristine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 58
- States / cities
- Aurora, Illinois • Chicago, Illinois • Joliet, Illinois + 43 more
- Conditions
- Chronic Inflammatory Demyelinating Neuropathy
- Interventions
- Alemtuzumab infusion
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Interventions
- alemtuzumab, ofatumumab, biopsy
- Biological · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Leukemia, Lymphoma
- Interventions
- alemtuzumab, rituximab, pentostatin, sargramostim
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Rochester, Minnesota • Charlottesville, Virginia
- Conditions
- Renal Transplantation
- Interventions
- Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Sickle Cell Disease, Beta Thalassemia-Major
- Interventions
- alemtuzumab (Campath IH), Fludarabine, Melphalan, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Hematopoietic Stem Cell Transplantation
- Drug · Biological
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- alemtuzumab GZ402673
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,062 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 52
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
- Conditions
- Sickle Cell Disease
- Interventions
- Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
- Drug · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 35
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
- Conditions
- Sickle Cell Disease, Beta Thalassemia
- Interventions
- Busulfan, Fludarabine, Alemtuzumab, Allogeneic stem cell transplant
- Drug · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Early Highly Effective Therapies Group, Escalation Therapies Group
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 15
- States / cities
- Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
- Conditions
- T-Cell Lymphoma, Lymphoma, Non-Hodgkin's
- Interventions
- CHOP and alemtuzumab
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sickle Cell Anemia, Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pure Red Cell Aplasia
- Interventions
- Campath, Chemo and/or TBI Allo SCT
- Drug
- Lead sponsor
- David Rizzieri, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Durham, North Carolina